This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva files EU court challenge over antitrust fine for MS-drug abuse

By Lewis Crofts ( January 15, 2025, 15:24 GMT | Insight) -- Teva Pharmaceuticals has taken its fight against a 462.6 million euro antitrust fine to EU judges, disputing a decision in October that said the company had misused the patent system and spread false information to protect a multiple sclerosis drug. The appeal is the latest challenge to the EU's use of dominance-abuse rules, and will chart novel legal territory, being the first time this kind of conduct has been sanctioned under the bloc's competition law.Teva Pharmaceuticals has appealed to EU judges to overturn a 462.6 million euro fine imposed for misusing the patent system and for spreading false information to protect its leading multiple sclerosis drug....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections